Regulatory Fate of Cancer Indications in the European Union After Accelerated Approval in the US.
作者信息
Petersen Tonny Studsgaard, Karstoft Kristian, Sørup Freja Karuna Hemmingsen, Lund Marie, Cramer Allan
机构信息
Department of Clinical Pharmacology, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark.
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
出版信息
JAMA Oncol. 2025 Jan 1;11(1):70-71. doi: 10.1001/jamaoncol.2024.5145.
Abstract
摘要
相似文献
1
Regulatory Fate of Cancer Indications in the European Union After Accelerated Approval in the US.
JAMA Oncol. 2025 Jan 1;11(1):70-71. doi: 10.1001/jamaoncol.2024.5145.
2
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval.
JAMA Intern Med. 2021 Apr 1;181(4):490-498. doi: 10.1001/jamainternmed.2020.8441.
3
Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021.
JAMA Health Forum. 2022 Aug 5;3(8):e222685. doi: 10.1001/jamahealthforum.2022.2685.
4
Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Milbank Q. 2020 Dec;98(4):1219-1256. doi: 10.1111/1468-0009.12476. Epub 2020 Oct 6.
5
Clinical development time is shorter for new anticancer drugs approved via accelerated approval in the US or via conditional approval in the EU.
Clin Transl Sci. 2023 Jul;16(7):1127-1133. doi: 10.1111/cts.13519. Epub 2023 Apr 4.
6
Comparing supplemental indications for cancer drugs approved in the US and EU.
Eur J Cancer. 2024 Nov;212:114330. doi: 10.1016/j.ejca.2024.114330. Epub 2024 Sep 12.
7
A detailed analysis of expedited regulatory review time of marketing authorization applications for new anticancer drugs in the US and EU.
Clin Transl Sci. 2022 Aug;15(8):1959-1967. doi: 10.1111/cts.13308. Epub 2022 May 31.
8
National Comprehensive Cancer Network Guideline Recommendations of Cancer Drugs With Accelerated Approval.
JAMA Netw Open. 2023 Nov 1;6(11):e2343285. doi: 10.1001/jamanetworkopen.2023.43285.
9
US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018.
JAMA Netw Open. 2022 Sep 1;5(9):e2230973. doi: 10.1001/jamanetworkopen.2022.30973.
10
Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway.
J Pharm Policy Pract. 2024 Jun 4;17(1):2351003. doi: 10.1080/20523211.2024.2351003. eCollection 2024.
引用本文的文献
1
Current landscape of US Food and Drug Administration use of expedited regulatory approvals for colorectal cancer care.
J Manag Care Spec Pharm. 2025 Sep;31(9):929-936. doi: 10.18553/jmcp.2025.31.9.929.
2
Cancer drug applications to the EMA and the FDA: A comparison of new drugs and extension of indication in terms of approval decisions and time in review.
Br J Clin Pharmacol. 2025 May;91(5):1431-1438. doi: 10.1111/bcp.16391. Epub 2025 Jan 7.
本文引用的文献
1
Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval.
JAMA. 2024 May 7;331(17):1471-1479. doi: 10.1001/jama.2024.2396.
2
Withdrawn accelerated approvals for cancer indications in the USA: what is the marketing authorisation status in the EU?
Lancet Oncol. 2023 Sep;24(9):e385-e394. doi: 10.1016/S1470-2045(23)00357-1.
3
Cancer Drug Prices in the United States: Efficacy, Innovation, Clinical Trial Evidence, and Epidemiology.
Value Health. 2023 Nov;26(11):1590-1600. doi: 10.1016/j.jval.2023.06.020. Epub 2023 Jul 28.
4
Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021.
JAMA Health Forum. 2022 Aug 5;3(8):e222685. doi: 10.1001/jamahealthforum.2022.2685.
5
Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019.
JAMA Netw Open. 2022 Jun 1;5(6):e2216183. doi: 10.1001/jamanetworkopen.2022.16183.
Zotero 插件